This platform in molecular pharmacology and pharmacokinetics-pharmacodynamics (PK-PD) led by the University of Liverpool provides new drug development models and approaches to help industry overcome barriers posed by antimicrobial resistance. It supports the discovery and development of novel therapeutics to tackle the world’s most critical, multi-drug-resistant infections.
The multi-drug-resistant superbug Acinetobacter baumannii is categorised by the World Health Organisation (WHO) as a critical priority pathogen that is a key threat to human health at a global scale. New drugs are urgently required; however, robust tools to assess these compounds at the early therapeutic lead stage are poorly developed. To support industrial innovation, we are extending a suite of model systems that enable new therapeutic solutions for Acinetobacter baumannii. These include new model systems of hospital acquired pneumonia, which continues to be associated with unacceptably high mortality.
For more information or to learn how your business can engage with this platform.